As the SGLT-2 inhibitor Jardiance expanded its scope to a treatment for chronic heart failure unrelated to heart rate, expectations were also expressed in the clinical field. The medical staff said, "We changed the paradigm of heart failure treatment. There are also non-payment areas, but the burden of drug prices is low, so we are actively using Jardiance as a "non-reimbursement."

Beringer Ingelheim Korea and Lilly Korea held a press conference on the 12th to commemorate the expansion of the adaptation of the SGLT-2 inhibitor Jardiance. Kang Seok-min, a professor of cardiology at Yonsei Severance Hospital, and Cho Hyun-jae, a professor of cardiology at Seoul National University Hospital and Yoon Jong-c